Insider Selling: Fennec Pharmaceuticals (TSE:FRX) Director Sells 8,346 Shares of Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Chris Anigeron Rallis sold 8,346 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of C$9.67, for a total transaction of C$80,705.82. Following the completion of the sale, the director directly owned 61,314 shares in the company, valued at C$592,906.38. This represents a 11.98% decrease in their ownership of the stock.

Chris Anigeron Rallis also recently made the following trade(s):

• On Monday, May 11th, Chris Anigeron Rallis bought 14,344 shares of Fennec Pharmaceuticals stock. The stock was bought at an average cost of C$3.35 per share, for a total transaction of C$48,052.40.

Fennec Pharmaceuticals Stock Performance

FRX remained flat at C$9.65 on Monday. 101 shares of the company were exchanged, compared to its average volume of 1,106. The business has a 50-day moving average of C$9.50 and a 200 day moving average of C$10.46. The stock has a market capitalization of C$334.98 million, a P/E ratio of -28.38 and a beta of 3.22. Fennec Pharmaceuticals Inc. has a 1-year low of C$7.59 and a 1-year high of C$13.83.

Wall Street Analyst Weigh In

Separately, B. Riley Financial raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, According to MarketBeat, Fennec Pharmaceuticals has an average rating of “Strong Buy”.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.